iCell Gene Therapeutics Announces Upcoming Conference PresentationsSTONY BROOK, N.Y., Oct. 05, 2026 (GLOBE NEWSWIRE) -- iCell Gene Therapeutics ("iCell Gene"), a clinical-stage biopharmaceutical company developing autologous and in vivo CAR T cell therapies for autoimmune diseases and cancer, today announced that Jennifer Chow, CEO will present and meet with investors and potential partners at the following upcoming conference:
iCell Presents Positive New Follow-up Clinical Data Confirming BCMA CD19 cCAR Safely Delivers Long-term Medication Free Complete Remission from Systemic Lupus Erythematosus & Lupus Nephritis at EULAR 2024
iCell Gene Therapeutics, Inc., a clinical-stage biotechnology company focused on the research and development of proprietary CAR immunotherapies for patients with unmet medical needs in autoimmune diseases and cancer, today announced new longer-term follow-up data from the Company’s BCMA CD19 compound chimeric antigen receptor (cCAR) T cell immunotherapy development program. The new data were part of iCell’s oral presentation regarding results of the investigator-initiated Phase 1 clinical trial of the BCMA CD19 cCAR in systemic lupus erythematosus (SLE) patients with lupus nephritis (LN) at the European Alliance of Associations for Rheumatology (EULAR) 2024 Congress taking place from June 12-15 in Vienna, Austria.
iCell Gene Therapeutics Announces Positive Clinical Data from Investigator Initiated Phase 1 Trial Evaluating BCMA-CD19 Compound CAR in Patients with Systemic Lupus Erythematosus/Lupus Nephritis Published in Annals of the Rheumatic Diseases
iCell Gene Therapeutics, a clinical stage biopharmaceutical company focused on immunotherapies for autoimmune disorders and cancer, today announced the publication in Annals of the Rheumatic Diseases of positive results of an investigator initiated clinical trial (IIT) for its BCMA-CD19 compound chimeric antigen receptor (cCAR) T cell immunotherapy.
